Testoluten

A peptide-complex extract from animal testicular tissue, sold as oral capsules within the Khavinson bioregulator line and marketed for male reproductive support, with no published sequence, no identified target, and no compound-specific human trials.

Also referenced as: Testoluten A-13, A-13 peptide bioregulator, Cytomax Testoluten, Testoluten lingual

Also appears in: Longevity

What is Testoluten?

Testoluten is a peptide-complex extract prepared from testicular tissue of young animals, sold in oral capsules and marketed as a tissue-specific “bioregulator” for the male reproductive system. It belongs to the natural-extract arm of the short-peptide program run by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, where it carries the catalog code A-13, and it is the extract counterpart to Testagen, the synthetic tetrapeptide Lys-Glu-Asp-Gly from the same program. That A-13 designation is a retail product code for the line, not a chemical identifier, and it does not appear anywhere in the scientific literature.

The shared naming hides an important difference. Testoluten is peptide material, but it is not a defined molecule: it is an undefined low-molecular-weight fraction isolated from animal tissue, with no published sequence, no single molecular weight, and no identified active constituent. The purity percentage and mass-spectrometry trace that document a synthetic research peptide have nothing to attach to here. It appears in the research-compound market because the Khavinson line is sold as a family, and because male reproductive support is a high-demand category where the actual hormonal options are prescription drugs.

How it works

The proposed mechanism is inherited from the broader Khavinson program rather than demonstrated for this extract:

• Nuclear entry and sequence-selective DNA binding — fluorescein-labeled short peptides from the program, including Testagen (Lys-Glu-Asp-Gly), produced marked fluorescence in the cytoplasm, nucleus, and nucleolus of HeLa cells, and quenched the fluorescence of labeled deoxyribooligonucleotides to differing degrees depending on peptide sequence, which the authors read as sequence-selective interaction with DNA. Testagen grouped with the peptides preferring CAG-containing sequences; the CNG preference reported in the same paper belongs to epithalon, pinealon, and bronchogen (Fedoreyeva et al., Biochemistry (Moscow), 2011, 76(11):1210–1219). This was the synthetic tetrapeptide in cell culture, not the testis extract.
• Gene-expression framework — the program’s systematic review argues that peptides of two to seven residues enter the nucleus, interact with DNA and histones, and influence DNA methylation status, positioning short peptides as epigenetic regulators across species (Khavinson et al., Molecules, 2021, 26(22):7053).
• The “peptide deficiency” premise — the underlying theory holds that aging is a determined shift in gene expression that impairs synthesis of tissue-specific regulatory peptides, and that supplying organ-matched peptides offsets that deficit (Khavinson, Neuroendocrinology Letters, 2002, 23 Suppl 3:11–144). Organ specificity is asserted by tissue of origin; no receptor, transporter, or molecular target has been identified for the testis extract.
• Animal geroprotection at the program level — long-term treatment with some preparations from this program increased mean lifespan by 20–40% in rodents and suppressed tumorigenesis, both spontaneous and induced by chemical or radiation carcinogens (Anisimov & Khavinson, Biogerontology, 2010, 11(2):139–149). Those results describe the program’s preparations collectively; the testis extract is not among the ones with published rodent lifespan data.

Research status

No human trial of Testoluten has been published or registered. PubMed indexes zero records for the term, and ClinicalTrials.gov lists zero registered studies naming it (both checked August 2026); a registry search for “peptide bioregulator” returns nothing either. There is no Phase 1, no pharmacokinetic study, and no controlled comparison against placebo or against an established hormonal therapy.

What exists instead is program-level literature from a single research group.

• Khavinson’s 2002 monograph-length review sets out the peptide theory of aging and the geroprotective data for Epithalamin, the pineal extract from the same line (Neuroendocrinology Letters, 2002, 23 Suppl 3:11–144).
• Anisimov & Khavinson (2010) summarize decades of rodent work, reporting mean lifespan increases of 20–40% for some preparations and referencing 6–12 years of clinical application — without per-preparation trial reports retrievable in the indexed literature (Biogerontology, 11(2):139–149).
• Fedoreyeva et al. (2011) supply the cell-level mechanism evidence, and did so with synthetic tetrapeptides rather than any tissue extract (Biochemistry (Moscow), 76(11):1210–1219).
• Khavinson et al. (2021) review the gene-regulation model, again from the originating group (Molecules, 26(22):7053).

Across all of it, independent replication outside the originating group is absent, and no publication reports an outcome measured on Testoluten itself.

A frequently mis-attributed result. Vinogradova et al. reported that the synthetic tetrapeptide epithalon (Ala-Glu-Asp-Gly), injected subcutaneously at 0.1 µg per rat five times a week from four months of age until natural death, significantly inhibited the development of spontaneous tumors in male rats kept under altered illumination regimens — primarily testicular leydigomas and leukemias — while leaving mean lifespan virtually unchanged (Bulletin of Experimental Biology and Medicine, 2008, 145(4):472–477). Because the tumor endpoint is testicular, this study is sometimes offered in support of testis-targeted bioregulators. It tested a different compound — a defined synthetic peptide from the pineal branch of the program — delivered by injection, and it measured tumor incidence rather than reproductive function.

Marketing claims outrun the record. Product copy for this compound routinely states that its effectiveness was established in clinical studies, and lists testicular hypofunction, male infertility, low blood testosterone, and recovery after ionizing radiation or toxic exposure among the conditions addressed. No indexed publication supporting those specific claims is retrievable, and no regulatory authority has reviewed them. They are assertions, not findings.

Oral delivery is an open question, not a solved one. The product is a swallowed capsule, and peptides face well-characterized proteolytic and permeability barriers in the gastrointestinal tract; the oral peptide drugs that reached approval required enabling formulation technology to overcome them (Drucker, Nature Reviews Drug Discovery, 2020, 19(4):277–289). No published pharmacokinetic work shows that intact peptides from a testis extract survive digestion, enter circulation, or reach testicular tissue.

Common dosage forms

• Oral capsules — the standard format, labeled 10 mg of peptide complex A-13 per capsule and sold in 20- and 60-count boxes, with the 20-count pack marketed as a ten-day course. The milligram figure describes extract mass, not a quantity of any identified peptide, so it is not comparable to the milligram strength printed on a synthetic peptide vial.
• Sublingual (“lingual”) form — the same extract supplied as a liquid taken as drops under the tongue, labeled 10 mg of peptide complex A-13 per 1 ml daily dose, and sold on the premise that buccal absorption bypasses the gut. That premise is untested for this material, and the labeled milligrams again describe extract mass rather than a defined active.
• No injectable presentation — unlike most research-market peptides, this extract line is sold only for oral or sublingual use. Vials of lyophilized powder marketed for the same tissue target generally contain Testagen, the synthetic tetrapeptide, which is a different product.
• No approved dosage form exists, so there is no reference labeling, no assigned strength, and no compendial monograph against which a given capsule can be checked.

Key considerations

• No approved status in the United States. Testoluten holds no FDA approval, no NDA or BLA, and no reference labeling. It reaches the U.S. market as an imported dietary supplement — a category in which products are not evaluated by FDA for safety or effectiveness before they are marketed. Availability in that category is not a finding about either.
• Tissue sourcing is the quality question, and purity certificates do not answer it. FDA’s 2016 final rule defines “prohibited cattle materials” and bars them from human food, dietary supplements, and cosmetics. Specified risk materials are one part of that definition — brain, skull, eyes, trigeminal ganglia, spinal cord, vertebral column, and dorsal root ganglia from cattle 30 months and older, plus tonsils and distal ileum from all cattle — and testicular tissue is not among them. But the definition does not stop at tissue type: it also reaches material from non-ambulatory disabled cattle, material from cattle not inspected and passed, and mechanically separated beef. So a bovine testes extract is not prohibited by virtue of the tissue, yet whether a given lot is compliant still turns on the age, health, and inspection status of the animals behind it — country of origin and herd controls, questions that HPLC purity documentation, the standard paperwork for synthetic peptides, does not address.
• This is not a hormonal therapy and does not share a mechanism with one. hCG acts on the LH/hCG receptor and gonadorelin on the GnRH receptor — each a defined molecule with a known receptor target, and hCG a licensed U.S. prescription biologic with approved labeling. Testoluten has no identified receptor, contains no steroid, and has no demonstrated effect on any hormone axis. It is filed here under the tissue system it is marketed for, not because any hormonal action has been shown. The “Test-” prefix refers to the tissue of origin, not to testosterone.
• The naming overlap inside the product line causes real confusion. Testoluten (natural extract, A-13) and Testagen (synthetic Lys-Glu-Asp-Gly) are separate products from the same program aimed at the same tissue. PubMed indexes two records mentioning Testagen and none mentioning Testoluten: the small body of published mechanism work names the synthetic peptide, while the efficacy claims attach to the extract. Evidence cited for one is not evidence for the other.
• Absence of reported harms is not a safety record. With no trials, no published pharmacokinetics, and no drug-level post-marketing surveillance, there is no adverse-event dataset for this compound in either direction. An extract of undefined composition also carries batch-to-batch variability that no released specification currently constrains.